about
Control of a neuronal morphology program by an RNA-binding zinc finger protein, UnkemptGenome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemiaPharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.Reversible suppression of an essential gene in adult mice using transgenic RNA interferenceCDK6 as a key regulator of hematopoietic and leukemic stem cell activationToward understanding and exploiting tumor heterogeneityRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaGene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators.Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma modelInhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationPax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.Reversible suppression of cyclooxygenase 2 (COX-2) expression in vivo by inducible RNA interference.The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.The histone chaperone CAF-1 safeguards somatic cell identity.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1TAp63 induces senescence and suppresses tumorigenesis in vivo.Development of siRNA payloads to target KRAS-mutant cancer.CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaAn oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancerMLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitorsFlt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.Preclinical efficacy of MEK inhibition in Nras-mutant AML.Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.An optimized microRNA backbone for effective single-copy RNAi.Functional identification of optimized RNAi triggers using a massively parallel sensor assay.Dissection of signal-regulated transcriptional modules by signaling pathway interference in oncogene-transformed cells.A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth.Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesisAn integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.A rapid and scalable system for studying gene function in mice using conditional RNA interference.Direct and indirect targeting of MYC to treat acute myeloid leukemiaA cluster of cooperating tumor-suppressor gene candidates in chromosomal deletionsAn insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi.
P50
Q24321460-05D4C8B1-D4D9-4C6D-B2AD-02DB3D066508Q24596097-08FC4120-6084-4132-9B11-6F0474D8A912Q27853186-F6BF84F9-E1D4-431D-88DB-70E72F68AFEDQ28512942-8C3801FA-8FDB-4CA5-88C7-0D2299EB9680Q28587749-8A3202DF-0DA4-45AE-ADF3-C770FC73BC3DQ28603034-AD76111C-8F44-4960-BA7C-88D7D146C351Q29617201-13828B6A-27A5-49EF-9E97-1817DE8FE709Q30779002-DF7FBA81-E6FC-4DF8-9E13-590329C240B8Q33693027-D7AD8994-FF51-4B16-991B-1ED93918B599Q33731216-837FFA71-F4D6-4571-BAF0-92288DB74D86Q33789597-52BDA710-B3E3-4448-AB5B-D2E1801BC041Q33794291-56A65FAB-2F70-448C-909C-65B3FCA12534Q33838294-A8BD8B67-EF4F-4259-804D-1F3BD31F110BQ33915185-7E8BB33A-E6D4-437D-A657-1EB6B73437DFQ33953631-2F5B00B0-EB5C-4F50-B92C-E4FBB530A245Q34045599-461186E5-9C0C-46A2-AA43-EF61E49BB669Q34048020-0117B4D0-1496-4557-A289-F20035B0E678Q34060915-FB0F0D54-D0CB-4FAE-869D-0D23F99DF5C1Q34287993-38528AC9-A397-41F7-ADD3-572795DAFC24Q34342934-EB0F8532-FD32-4104-97A5-DA67F3865406Q34345765-A3D1647E-356D-4BBC-8AB6-E5CEA4D84992Q34386922-A21CA3D5-8A08-4585-84E5-97FE22E57CD9Q34388531-92C41470-C45B-4352-AA5F-BFF7530A9621Q34658892-638C8690-73F8-4B03-8878-9EBA1FA19150Q34709391-30EA3ECC-3166-4881-8B4B-7F3B8140CD0BQ34737521-5681D52E-51FD-4BD6-802E-6ED07DF372D0Q35018971-0A0FF2E4-059B-49D4-A4C2-3CE95205F924Q35065928-49F68EFD-CC22-4F3A-8F18-6254F29E8717Q35088838-2DA55D69-C36E-4E74-A0F4-FBC867E80842Q35147447-8603AEC3-7129-4815-AF2E-60F6034E9790Q35173269-076BEFB1-19C5-48AA-A276-71C3A1886F4AQ35196919-7793B925-17DF-4E78-88C2-E5B9191C35CFQ35237394-25633D8C-9466-4B40-A403-790ABF4D2DFDQ35250612-DB081C55-45CB-414B-B780-EBDF0B2DD50EQ35627849-387EFE96-FBE8-4E46-9F9B-D8C828B2ED91Q35798798-196C3906-8F36-48C4-A2E4-B23520BCA82FQ35991696-0F48D6DA-4E92-4B34-B9E3-9DAF0F57B292Q35995227-EF7A0C9A-12B1-4E35-A278-254D970E304EQ36012341-20929BF0-25AD-497F-AB1B-B4BFF06151DEQ36088050-6E25BEA1-C10B-4526-B3EB-2AAD08694C63
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Johannes Zuber
@ast
Johannes Zuber
@en
Johannes Zuber
@es
Johannes Zuber
@nl
Johannes Zuber
@sl
type
label
Johannes Zuber
@ast
Johannes Zuber
@en
Johannes Zuber
@es
Johannes Zuber
@nl
Johannes Zuber
@sl
altLabel
Zuber J
@en
prefLabel
Johannes Zuber
@ast
Johannes Zuber
@en
Johannes Zuber
@es
Johannes Zuber
@nl
Johannes Zuber
@sl
P108
P106
P108
P21
P31
P496
0000-0001-8810-6835
P569
2000-01-01T00:00:00Z